| scholarly article | Q13442814 |
| P2093 | author name string | A V Shalygin | |
| E V Kaznacheyeva | |||
| V A Vigont | |||
| Y A Kolobkova | |||
| P2860 | cites work | Amyloid-mediated sequestration of essential proteins contributes to mutant huntingtin toxicity in yeast | Q21134910 |
| Huntingtin interacting proteins are genetic modifiers of neurodegeneration | Q21145230 | ||
| Huntingtin-associated protein-1 is a modifier of the age-at-onset of Huntington's disease | Q24306416 | ||
| Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1 | Q24310249 | ||
| Ca2+-dependent block of CREB-CBP transcription by repressor DREAM. | Q24534305 | ||
| Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model | Q24647950 | ||
| Alzheimer's disease: the silver tsunami of the 21(st) century | Q26747610 | ||
| Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes | Q42714345 | ||
| Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay | Q42741104 | ||
| EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs | Q42963836 | ||
| STIM1 Protein Activates Store-Operated Calcium Channels in Cellular Model of Huntington's Disease. | Q43074970 | ||
| Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease | Q43120924 | ||
| N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. | Q43572870 | ||
| Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles | Q43821150 | ||
| Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. | Q43901593 | ||
| Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. | Q44068407 | ||
| Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain | Q44092333 | ||
| Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice | Q44131699 | ||
| The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. | Q44376761 | ||
| Increased thirst and drinking in Huntington's disease and the R6/2 mouse | Q45289234 | ||
| DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease | Q45290752 | ||
| Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons | Q45291149 | ||
| A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. | Q45292888 | ||
| Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice | Q45296049 | ||
| Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. | Q45297039 | ||
| Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. | Q45297497 | ||
| Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice | Q45298466 | ||
| Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease | Q45298474 | ||
| A putative Drosophila homolog of the Huntington's disease gene | Q45298821 | ||
| New concepts of pathogenesis, diagnosis, and treatment of neurodegenerative diseases | Q45299955 | ||
| The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes | Q45304409 | ||
| Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice | Q45304684 | ||
| A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease | Q45305713 | ||
| Ca2+ dysregulation in neurons from transgenic mice expressing mutant presenilin 2. | Q47376075 | ||
| Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. | Q48373564 | ||
| Calcium activation of the LMO4 transcription complex and its role in the patterning of thalamocortical connections. | Q48450758 | ||
| Huntington disease | Q48465200 | ||
| Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin | Q77906721 | ||
| Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease | Q27011417 | ||
| Secondary Structure of Huntingtin Amino-Terminal Region | Q27657408 | ||
| Structure and Topology of the Huntingtin 1–17 Membrane Anchor by a Combined Solution and Solid-State NMR Approach | Q27679485 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease | Q27933811 | ||
| The hunt for huntingtin function: interaction partners tell many different stories | Q28203006 | ||
| Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation | Q28246858 | ||
| Huntington's disease | Q28284355 | ||
| Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death | Q28287762 | ||
| Shaping the role of mitochondria in the pathogenesis of Huntington's disease | Q28384036 | ||
| Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease | Q28512442 | ||
| Calcium oscillations increase the efficiency and specificity of gene expression | Q29614728 | ||
| Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain | Q29617982 | ||
| The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans | Q29619760 | ||
| Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. | Q30168237 | ||
| Effects of overexpression of huntingtin proteins on mitochondrial integrity | Q30489322 | ||
| Calpain inhibition mediates autophagy-dependent protection against polyglutamine toxicity. | Q30620357 | ||
| Regional and cellular gene expression changes in human Huntington's disease brain | Q33233457 | ||
| Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin | Q33588238 | ||
| Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. | Q33850154 | ||
| Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. | Q33857802 | ||
| Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets | Q33869998 | ||
| Development of biomarkers for Huntington's disease | Q33907629 | ||
| Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death | Q33949349 | ||
| Proteostasis in striatal cells and selective neurodegeneration in Huntington's disease | Q34014433 | ||
| Genetic ablation and chemical inhibition of IP3R1 reduce mutant huntingtin aggregation. | Q34067919 | ||
| Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients | Q34470414 | ||
| Mouse models of Huntington's disease | Q34502714 | ||
| Mechanisms of disease: Histone modifications in Huntington's disease | Q34560517 | ||
| Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli | Q34605764 | ||
| Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates | Q34634976 | ||
| Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease | Q38193991 | ||
| Corticostriatal synaptic adaptations in Huntington's disease | Q38362877 | ||
| Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease | Q38408049 | ||
| Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells | Q38462208 | ||
| Mitochondrial Ca(2+) in neurodegenerative disorders. | Q38503500 | ||
| Attenuated presenilin-1 endoproteolysis enhances store-operated calcium currents in neuronal cells. | Q38931016 | ||
| The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity | Q39382468 | ||
| Calcium signaling and neurodegenerative diseases | Q39463322 | ||
| Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression. | Q39490292 | ||
| Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. | Q39626047 | ||
| Changes in the store-dependent calcium influx in a cellular model of Huntington's disease | Q39667228 | ||
| Mitochondrial uptake of calcium ions and the regulation of cell function | Q39872398 | ||
| Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease | Q40031554 | ||
| Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease. | Q40149501 | ||
| Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients | Q40207281 | ||
| Both Orai1 and TRPC1 are Involved in Excessive Store-Operated Calcium Entry in Striatal Neurons Expressing Mutant Huntingtin Exon 1. | Q40243449 | ||
| Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. | Q40373593 | ||
| Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. | Q40515168 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. | Q40721588 | ||
| Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila | Q41705884 | ||
| The Neuronal Functions of EF-Hand Ca2+-Binding Proteins | Q41782605 | ||
| Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity | Q42042260 | ||
| Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage | Q42512972 | ||
| High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. | Q34742691 | ||
| Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus | Q34774875 | ||
| Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment | Q35072356 | ||
| The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size | Q35238524 | ||
| Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse | Q35345762 | ||
| Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease | Q35542530 | ||
| Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease | Q35645271 | ||
| Orai proteins interact with TRPC channels and confer responsiveness to store depletion. | Q35721728 | ||
| Calcium Handling by Endoplasmic Reticulum and Mitochondria in a Cell Model of Huntington's Disease. | Q35906784 | ||
| Inhibition of store-operated calcium entry by sub-lethal levels of proteasome inhibition is associated with STIM1/STIM2 degradation | Q35951618 | ||
| A historical review of cellular calcium handling, with emphasis on mitochondria. | Q36088211 | ||
| Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood | Q36116666 | ||
| A mathematical model of pre-diagnostic glioma growth. | Q36145414 | ||
| Ca2+-dependent transcriptional control of Ca2+ homeostasis. | Q36234688 | ||
| 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. | Q36318579 | ||
| Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model. | Q36431970 | ||
| Store-operated calcium channels and pro-inflammatory signals. | Q36513347 | ||
| Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm | Q36514656 | ||
| Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease | Q36588268 | ||
| N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease | Q36692396 | ||
| Mitochondrial Ca2+ as a key regulator of cell life and death | Q36790546 | ||
| Huntingtin's spherical solenoid structure enables polyglutamine tract-dependent modulation of its structure and function | Q36839701 | ||
| Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. | Q36861129 | ||
| Contribution and regulation of TRPC channels in store-operated Ca2+ entry | Q37300474 | ||
| Expression of genes encoding the calcium signalosome in cellular and transgenic models of Huntington's disease. | Q37338808 | ||
| Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration | Q37384081 | ||
| Oxidative metabolism and Ca2+ handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington's disease | Q37530288 | ||
| Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin | Q37613283 | ||
| Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease | Q37776087 | ||
| Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease. | Q37839534 | ||
| Learning and memory in Drosophila: behavior, genetics, and neural systems. | Q37929941 | ||
| Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits | Q37997321 | ||
| Influence of species differences on the neuropathology of transgenic Huntington's disease animal models | Q38022914 | ||
| Neuronal Ca(2+) dyshomeostasis in Huntington disease. | Q38074521 | ||
| Releasing the brake: restoring fast axonal transport in neurodegenerative disorders. | Q38148914 | ||
| P433 | issue | 2 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 34-46 | |
| P577 | publication date | 2017-04-01 | |
| P1433 | published in | Acta Naturae | Q27723435 |
| P1476 | title | Huntington's Disease: Calcium Dyshomeostasis and Pathology Models | |
| P478 | volume | 9 |
| Q64994188 | Expression of Ca2+-Binding Buffer Proteins in the Human and Mouse Retinal Neurons. |
| Q59129873 | Huntingtin-Associated Protein 1A Regulates Store-Operated Calcium Entry in Medium Spiny Neurons From Transgenic YAC128 Mice, a Model of Huntington's Disease |
| Q64075331 | Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications |
| Q64911482 | Live-Cell Imaging of Physiologically Relevant Metal Ions Using Genetically Encoded FRET-Based Probes. |
| Q55606266 | Patient-Specific iPSC-Based Models of Huntington’s Disease as a Tool to Study Store-Operated Calcium Entry Drug Targeting. |
| Q90228537 | Regulation of Membrane Calcium Transport Proteins by the Surrounding Lipid Environment |
| Q57818216 | T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease |
Search more.